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admitted to the ICU (OR1.027, CI1.016-1.037; p.0001), and readmitted at 30
(OR1.129, CI1.118-1.141; p.0001), 90 (OR1.185, CI1.175-1.196; p.0001), and
180 (OR1.163, CI 1.153-1.173; p.0001) days post discharge compared to
non-HN patients. CONCLUSIONS: HN represents a significant clinical, utiliza-
tion, and economic burden due to increased cost, LOS, ICU admissions and
hospital readmission.
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OBJECTIVES: To evaluate and compare changes in healthcare resource utilization
and costs associated with the initiation of pregabalin or gabapentin in pDPN pa-
tients in a real-world setting.METHODS: A retrospective cohort study utilizing the
MarketScan Commercial Claims and Encounters Database (2007-2009). Patients
with a new prescription for pregabalin or gabapentin in 2008 (date of the prescrip-
tion defined as index date) and 1 healthcare encounter with an ICD-9 code for
diabetic peripheral neuropathy (DPN; 250.6 or 357.2) within 30 days prior to the first
prescription for pregabalin or gabapentin were identified and propensity score
matched. Both cohorts were continuously enrolled for the 12month pre- and post-
index periods during which health care utilization and costs were assessed. Pre- to
post-index changes were compared between pregabalin and gabapentin using a
difference-in-difference (DID) approach. RESULTS: 910 pregabalin patients (48.6%
female;mean age 63.312.1 years) werematched to 910 gabapentin patients (48.8%
female; mean age 63.312.1 years); other demographic and clinical characteristics
were also comparable between cohorts,with the exception of US region. The pre- to
post-index DID in resource utilization did not differ between the two cohorts in-
cluding: number of office visits per patient (P0.66), number of ER visits (P0.78),
number of inpatient stays (P0.92), average inpatient length of stay per hospital-
ization (P0.79), number of total prescriptions filled (P0.37). The DID of total
healthcare costs per patient were non-significant with pre- to post-index increases
of $3,081 in pregabalin patients and $4,683 in gabapentin patients (P0.50).
CONCLUSIONS: Patients with pDPN initiating pregabalin or gabapentin experi-
enced comparable changes in healthcare resource utilization and costs. These re-
sults suggest overall cost neutrality between pregabalin and gabapentin.
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OBJECTIVES: To identify the factors associated with high healthcare expenditure
among obese individuals in the United States. METHODS: Analytical sample con-
sisted of obese adults 20 years or olderwith (BMI30). Total yearly expenditures for
obese adults were obtained from 2007 Medical Expenditure Panel Survey data.
Observations with total yearly healthcare expenditure greater than 90th percentile
were classified as high healthcare expenders and coded yes/no to be used as the
dependent variable. Independent factors selected according to the Anderson’s Be-
havioral Model were age, gender, race, MSA, region, education, poverty category,
source of payment, usual source of care, MSA, education, general health status,
mental health status andmortality risk status. ‘Surveylogistic’ regressionwas used
to determine the predictors of high expenditures. RESULTS: Descriptive analysis
show that adults with high healthcare expenditure were whites (74.23%), hadmid-
school education (60%), lived in MSA (79%), had usual care provider (95%), private
insurance (67%) and belonged to very high mortality risk group (46%). In adjusted
analysis, age (OR: 1.019 CI: 1.009-1.029), usual source of care (OR: 1.901 CI: 1.196-
3.020), private (OR: 3.609 CI: 1.992-6.539) and public insurance (OR: 3.251 CI: 1.781-
5.936), very high (OR: 3.342 CI: 2.327-4.798) and high (OR: 2.213 CI: 1.666-2.938)
mortality risk and general health status (OR: 2.493 CI: 2.148-2.893) were associated
with high healthcare expenditure. CONCLUSIONS: Several enabling and need fac-
tors seem to be associated with high healthcare expenditure. Both private and
public health insurance have a significant burden of healthcare expenditure asso-
ciated with obesity. Individuals with usual source of care are more likely to incur
high healthcare expenditure. Comorbidities have a significant impact on health-
care expenditure among obese individuals and highlight the need to deliver com-
prehensive disease state management. The findings from this study can have im-
portant implications in understanding increased utilization of health services
among obese adults in the United States.
PSY29
A COMPARISON OF DAILY AVERAGE SUPPLY (DASUP) OF OXYCODONE AND
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OBJECTIVES: Although both oxycodone CR and oxymorphone ER are approved for
twice daily dosing, it is unclear whether actual utilization is consistent with this.
The objective was to assess whether there exist differences in the utilization of
oxycodone CR and oxymorphone ER.METHODS:We used prescription claims data
from a commercially-insured population (i3 InVision Data Mart database), during
the period January 1, 2007 to March 31, 2010. A claim for at least one 30-day supply
of study drug one month prior to the observation period was necessary to avoid
capturing utilization associated with titration. Subsequently, all subjects had a
claim for at least a 90-day supply of the respective opioid analgesic. Patients’ claims
were excluded from this analysis if there was evidence of a switch from one to the
other study opioid during the 90-day observation period. Therewere no limitations
on the use of other opioids, during the baseline or observation periods. The final
cohort consisted of 6,567 oxycodoneCRpatients and 796 oxymorphone ERpatients.
In addition to univariate analysis, multivariate analyses were conducted using
generalized linear models (GLM) to adjust for the observed heterogeneity among
patients in the observational database. RESULTS: The unadjusted daily average
supply (DASUP)mean values for the highest strengths of oxycodone CR (80mg)was
3.9 compared to 2.9 for oxymorphone ER (40mg), 3.0 vs. 2.4 for all lower strengths,
and 3.1 vs. 2.5 for all strengths. (all p0.001). After adjusting for baseline differ-
ences, a risk-adjusted overall mean difference in DASUP remainedwith oxycodone
CR patients receiving, on average, 0.6 tablets more per day than those dispensed
oxymorphone ER (p0.001). The direction, magnitude and statistical signifi-
cance of these differences were essentially unchanged in sensitivity analyses.
CONCLUSIONS: In managing the pharmacy benefit, decision-makers may want to
consider the financial implications of these DASUP differences.
Systemic Disorders/Conditions – Patient-Reported Outcomes & Preference-Based
Studies
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OBJECTIVES:There is a rapidly growing overweight and obesity epidemic in theUS,
and a high demand for long-term safe and effective weight-loss agents. While 3
new antiobesity therapies underwent FDA review in 2010, little is known about the
utilization of available weight-loss drugs. The objective of this analysis is to de-
scribe the real-world prescription patterns, adherence, and persistence of weight-
loss pharmacotherapy in the United States. METHODS: A retrospective cohort
analysis was conducted using Medco’s integrated claims database to evaluate
adult patients initiating weight-loss pharmacotherapy between May 2007-October
2010. Eligibility criteria included new weight-loss drug prescription claims (no
weight-loss therapy prescriptions 6 months prior to index claim date) and contin-
uous eligibility for 6months pre- and 14months post-index claim date. Patients on
drugs with 1000 distinct patient counts were analyzed for adherence (annual
Medication Possession Ratio; MPR), persistency (allowing a 45 day gap), and con-
comitant therapy. RESULTS: Analyses included 91,160 patients receiving five
drugs: phentermine (N67434), sibutramine (N13438), orlistat (N8047), phendi-
metrazine (N4631), and, diethylpropion (N 4350). MeanSD age was 4412
years (96%, 18-64 y/o), 82% were female, 46% resided in the South, and 91% filled
prescriptions at retail only. Among obesity drug prescribers with known specialty,
71% were family/internal medicine practitioners. Patients received a mean of 33
concomitant chronic medications, with 38%, 31%, 22%, and 11% on antihyperten-
sive, antidepressant, dyslipidemia, or oral antidiabetic therapy, respectively. The
mean adherence ranged fromMPR0.20 (phendimetrazine) toMPR0.26 (phenter-
mine). Persistence at 3, 6, and 12 months ranged respectively from 26%-38% (low-
phendimetrazine, high-phentermine), 9%-16% (low-phendimetrazine, high-sibut-
ramine), and 3%-6% (low-phendimetrazine, high-sibutramine). CONCLUSIONS:
Weight-loss pharmacotherapies in the United States were prescribed by primary
care physicians to predominantly younger, female patients on concomitant ther-
apy for common obesity-related conditions. Adherence and persistence to therapy
is low, even over short-term exposure, although treatment duration may extend
beyond recommendations in some cases (e.g., phentermine).
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OBJECTIVES:Hemophilia A is a rare but serious bleeding disorder caused by a blood
clotting factor VIII (FVIII) deficiency. To examine the impact of hemophilia A and
replacement FVIII therapies from a humanistic and economic perspective, a tar-
geted literature review was conducted. METHODS: Searches were conducted in
MEDLINE® and the National Health Service Economic Evaluation Database, using
disease, patient-reported outcome and economic-related key words, limited to
English articles published from January 2000-January 2010 (inclusive). From 653
abstracts retrieved, 34 full-text articles were selected for detailed consideration.
RESULTS: Findings revealed increased mortality rates and decreased life expec-
tancy among people with hemophilia A, compared with the general population.
This is largely attributed to the transmission of blood-borne viruses (e.g. HIV and
Hepatitis-C) due to use of plasma-derived FVIII (pdFVIII) concentrates. Improve-
ments in viral attenuation processes plus donor screening practices for pdFVIII
products have reduced the risks of viral transmission, but risk fromnon-enveloped
viruses and other unknown pathogens still exists. Newly developed recombinant
FVIII therapies minimize these risks; however, such therapies are not currently
widely available globally. All available FVIII therapies use demanding regimens
requiring regular time-consuming injections,which can be detrimental to patients’
health-related quality of life and limit adherence. Non-adherence is associated
with diminished product efficacy, poorer health outcomes and increasing eco-
nomic expenditure. Treating hemophilia A is costly, primarily due to the high
acquisition cost of replacement FVIII products. However, indirect costs (e.g. patient
disability) also contribute to economic burden. Prophylactic treatment, while ini-
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